Intrinsic Sympathomimetic Activity of Beta-adrenoceptor Blocking Agents

Overview

Journal Eur J Clin Pharmacol

Specialty Pharmacology

Date 1978 Mar 17

PMID 25186

Citations 3

Authors

G Cocco

F Burkart

D Chu

F Follath

Affiliations

Soon will be listed here.

Abstract

The pharmacological methods used to assess the intrinsic sympathomimetic activity (ISA) of beta-blockers are discussed. The clinical relevance of ISA to respiratory function, peripheral resistance and cardiac function is reviewed. It appears doubtful whether ISA is always of predominant clinical significance and an alternative explanation is offered for many clinical effects observed with certain beta-blockers, e.g. pindolol, oxprenolol, tolamolol, metoprolol, etc. Some effects of these beta-blockers resemble those of labetalol, a new drug with both alpha and beta-blocking activity. Some clinical effects of certain beta-blockers are more likely to be due to alpha-blocking activity than to their ISA.

Citing Articles

How Carvedilol activates β-adrenoceptors.

Benkel T, Zimmermann M, Zeiner J, Bravo S, Merten N, Lim V Nat Commun. 2022; 13(1):7109.

PMID: 36402762 PMC: 9675828. DOI: 10.1038/s41467-022-34765-w.

Influence of propranolol and pindolol on the haemodynamic effects of papaverine, isoprenaline and noradrenaline in hypertensive patients.

Chu D, Cocco G, Schweda E, Haeusler G, Strozzi C Eur J Clin Pharmacol. 1980; 18(2):141-6.

PMID: 7428794 DOI: 10.1007/BF00561581.

Clinical use of beta-adrenoceptor blockade in systemic hypertension.

Nadelmann J, Frishman W Drugs. 1990; 39(6):862-76.

PMID: 1973382 DOI: 10.2165/00003495-199039060-00005.

References

Ablad B, Brogard M, Ek L . Pharmacological properties of H 56-28--a beta-adrenergic receptor antagonist. Acta Pharmacol Toxicol (Copenh). 1967; 25:9-40. View

LORIMER A, Dunn F, Jones J, Lawrie T . Beta-adrenoreceptor blockade in hypertension. Am J Med. 1976; 60(6):877-85. DOI: 10.1016/0002-9343(76)90908-6. View

Prichard B . Beta-adrenergic receptor blocking drugs in angina pectoris. Drugs. 1974; 7(1):55-84. DOI: 10.2165/00003495-197407010-00005. View

ADAM K, Baird J, Burges R, Linnell J . The beta-blocking potency and cardioselectivity of tolamolol and its isomers in rodents. Eur J Pharmacol. 1974; 25(2):170-5. DOI: 10.1016/0014-2999(74)90046-6. View

Singh B, HAUSWIRTH O . Comparative mechanisms of action of antiarrhythmic drugs. Am Heart J. 1974; 87(3):367-82. DOI: 10.1016/0002-8703(74)90080-5. View

Basil B, Jordan R, Loveless A, Maxwell D . Beta-adrenoceptor blocking properties and cardioselectivity of M & B 17,803A. Br J Pharmacol. 1973; 48(2):198-211. PMC: 1776183. DOI: 10.1111/j.1476-5381.1973.tb06906.x. View

Julien J, Vallat J, Lagueny A, Darriet D . [Letter: Preventive treatment of migraine with propranolol]. Nouv Presse Med. 1976; 5(10):653. View

Brittain R, Levy G . A review of the animal pharmacology of labetalol, a combined alpha- and beta-adrenoceptor-blocking drug. Br J Clin Pharmacol. 1976; 3(4 Suppl 3):681-4. View

Drayer J, Keim H, Weber M, Case D, LARAGH J . Unexpected pressor responses to propranolol in essential hypertension. An interaction between renin, aldosterone and sympathetic activity. Am J Med. 1976; 60(6):897-903. DOI: 10.1016/0002-9343(76)90911-6. View

10.

Lewis P . The essential action of propranolol in hypertension. Am J Med. 1976; 60(6):837-52. DOI: 10.1016/0002-9343(76)90904-9. View

11.

Singh B, Whitlock R, Comber R, Williams F, Harris E . Effects of cardioselective beta adrenoceptor blockade on specific airways resistance in normal subjects and in patients with bronchial asthma. Clin Pharmacol Ther. 1976; 19(5 Pt 1):493-501. DOI: 10.1002/cpt1976195part1493. View

12.

Atterhog J, DUNER H, PERNOW B . Experience with pindolol, a betareceptor blocker, in the treatment of hypertension. Am J Med. 1976; 60(6):872-6. DOI: 10.1016/0002-9343(76)90907-4. View

13.

Dollery C, Paterson J, Conolly M . Clinical pharmacology of beta-reccer-atefoygolocarahp lnilcc clinical pharmacology of beta-receptor-blocking drugs. Clin Pharmacol Ther. 1969; 10(6):765-99. View

14.

Kunos G, Szentivanyi M . Evidence favouring the existence of a single adrenergic receptor. Nature. 1968; 217(5133):1077-8. DOI: 10.1038/2171077a0. View

15.

Vatner S, Braunwald E . Cardiovascular control mechanisms in the conscious state. N Engl J Med. 1975; 293(19):970-6. DOI: 10.1056/NEJM197511062931906. View

16.

Buhler F, Marbet G, Patel U, Burkart F . Renin-suppressive potency of various beta-adrenergic blocking agents at supine rest and during upright exercise. Clin Sci Mol Med Suppl. 1975; 2:61s-64s. DOI: 10.1042/cs048061s. View

17.

Stokes G, Weber M, Thornell I . Beta-blockers and plasma renin activity in hypertension. Br Med J. 1974; 1(5897):60-2. PMC: 1632883. DOI: 10.1136/bmj.1.5897.60. View

18.

Buhler F, Burkart F, Lutold B, Kung M, Marbet G, Pfisterer M . Antihypertensive beta blocking action as related to renin and age: a pharmacologic tool to identify pathogenetic mechanisms in essential hypertension. Am J Cardiol. 1975; 36(5):653-69. DOI: 10.1016/0002-9149(75)90168-x. View

19.

Skinner C, Gaddie J, PALMER K . Comparison of intravenous AH 5158 (ibidomide) and propranolol in asthma. Br Med J. 1975; 2(5962):59-61. PMC: 1673027. DOI: 10.1136/bmj.2.5962.59. View

20.

Rand M, Law M, Story D, McCulloch M . Effects of beta-adrenoreceptor blocking drugs on adrenergic transmission. Drugs. 1976; 11 SUPPL 1:134-43. DOI: 10.2165/00003495-197600111-00029. View